Cluster B: 7 High Throughput Screening

集群 B：7 高通量筛选

• 批准号: 9252409
• 负责人: Meng Wu
• 金额: $ 23.96万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9252409
• 关键词: Antibodies; Antisense Oligonucleotides; Applications Grants; Automation; Biological; Biological Assay; Biology; Biomedical Research; Cancer Biology; Cancer Center Support Grant; Cell Differentiation process; Cell Line; Cells; Chemicals; Clinical; Collection; Comprehensive Cancer Center; Data Set; Detection; Excretory function; FDA approved; Flow Cytometry; Fluorescence; Fluorescence Resonance Energy Transfer; Fostering; Funding; Generations; Genes; Genetic; Genomics Shared Resource; Goals; Grant; Lead; Libraries; Ligands; Malignant Neoplasms; Metabolism; Microscopy; Mission; Molecular; Molecular Probes; Neurites; Pathway Analysis; Pathway interactions; Patients; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phenotype; Phosphotransferases; Process; RNA Interference; Reader; Research; Research Design; Research Personnel; Resources; Robotics; Running; Services; Signal Pathway; Small Interfering RNA; System; Techniques; Testing; Therapeutic; Therapeutic antibodies; Tissues; Toxic effect; United States National Institutes of Health; Universities; Walking; Xenograft procedure; absorption; cancer cell; cancer therapy; cell motility; chemical synthesis; combinatorial; data management; design; drug development; drug discovery; genetic approach; genome-wide; high throughput screening; imaging system; in vitro testing; instrumentation; luminescence; member; miniaturize; new therapeutic target; novel; novel strategies; personalized cancer therapy; pre-clinical; preclinical development; protein expression; research facility; screening; small molecule; small molecule libraries; small molecule therapeutics; therapeutic development; trafficking; transcription factor

The UI High Throughput Screening Core (HTS) is a new Holden Comprehensive Cancer Center (HCCC) shared research resource that provides a high-throughput platform integrating robotics, detection systems, chemical /biologics libraries, data management, and expertise. HTS provides HCCC members with scalable early, pre-clinical development of therapeutics, including small molecule therapeutics, antibodies, siRNAs, antisense oligonucleotides and other biologics including patient-derived cell therapeutics. It also supports high throughput screening for studies exploring the biology of cancer. The automatic, miniaturized and parallel high-throughput approaches foster hit and lead generation for drug discovery and development through screening of systematic, unbiased large chemical/biologics libraries. These strategies also facilitate molecular probe discovery for mechanism-of-action (MOA) studies of chemical biology through screening of focused intellectually designed compound collections. In addition, these high- throughput approaches aid the interrogation of cells, especially those derived from patients. The HTS was established in 2012 by university sponsors including the HCCC and an NIH S10 Shared Instrumentation grant funding. HTS is equipped to perform high-throughput screening in 96-, 384- and 1536- well formats, with plate reader detection (Perkin-Elmer EnVision) using absorbance, fluorescence and luminescence, including advanced FRET and BRET techniques. HTS can also perform high content screening (HCS, Perkin-Elmer Operetta Confocal Imaging System) to detect and quantify phenotypic changes, i.e. cell differentiation, cell migration, neurite outgrowth, and target trafficking; or by fluorescence intensities for target protein expression, transcription factor or signaling pathway analysis. Systems available in the HTS are integrated with robotics for plate handling and assay execution, suitable for small- or large-scale compound library screens with “walk-away” levels of automation. HTS currently holds five “small molecule” libraries containing approximately 140,000 compounds. In addition, HTS is in the process of determining the need and feasibility of obtaining a biologics library, i.e. genome-wide siRNA, antibodies, and diverse cell lines. Overall, HTS is a shared research resource focused on scalable screening approaches for drug discovery and development, and molecular probe discovery for mechanism-of-action studies for cancer investigators across campus and beyond.

UI高通量筛选核心（HTS）是一个新的霍尔顿综合癌症中心（HCCC）。